Do analysts agree on Organon (OGN) stock's price target?
Apr 02, 2022 · Organon & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "OGN." Who are Organon & Co.'s major shareholders? Organon & Co.'s stock is owned by many different institutional and retail investors.
What is the new ticker symbol for OGN stock?
Find real-time OGN - Organon & Co stock quotes, company profile, news and forecasts from CNN Business.
What is Organon&Co’s stock symbol?
Apr 07, 2022 · About OGN. Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
How many shares of OGN stock do I get with MRK?
Real time Organon & Co. (OGN) stock price quote, stock graph, news & analysis.
Is OGN a good stock to buy?
Out of 8 analysts, 2 (25%) are recommending OGN as a Strong Buy, 1 (12.5%) are recommending OGN as a Buy, 5 (62.5%) are recommending OGN as a Hold, 0 (0%) are recommending OGN as a Sell, and 0 (0%) are recommending OGN as a Strong Sell. What is OGN's earnings growth forecast for 2022-2024?
What kind of company is OGN?
global healthcare companyOrganon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands.
Where did OGN stock come from?
Organon was formed as a result of Big Pharma Merck's decision to spin out its Established Brands, Women's Health and Biosimilars divisions into a new entity. Shares began trading in May, and traded at $37 in early June, before sliding in response to Q121 earnings.Jul 21, 2021
When did OGN go public?
On May 14, 2021, Organon's common stock started when issued trading under the ticker “OGN.Aug 13, 2021
Is ogn large cap?
As of April 2022 Organon has a market cap of $8.80 Billion. This makes Organon the world's 1696th most valuable company by market cap according to our data.
Will OGN stock pay a dividend?
OGN pays a dividend of $0.84 per share. OGN's annual dividend yield is 2.39%.
Why is OGN stock down?
OGN Stock Topples On Outlook The biggest declines stemmed from women's health and established brands divisions. Those units brought in a respective $381 million and $1.03 billion, down 10% and 6% year over year.Nov 11, 2021
What is cost basis for OGN spinoff?
Cost basis is the total amount that you paid for an investment, such as a stock. A spin-off occurs when a company divides itself into two or more pieces. If you own stock in a company that has a spin-off, the cost basis you have in the original company is divided amongst the resulting divisions.
Is Organon stock a buy?
Organon & Co. has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.
Is Organon & Co. a buy right now?
9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 5 ho...
When is Organon & Co.'s next earnings date?
Organon & Co. is scheduled to release its next quarterly earnings announcement on Monday, June 20th 2022. View our earnings forecast for Organon &...
How were Organon & Co.'s earnings last quarter?
Organon & Co. (NYSE:OGN) posted its earnings results on Wednesday, February, 16th. The company reported $1.37 EPS for the quarter, topping the Zack...
How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?
Organon & Co. declared a quarterly dividend on Friday, February 18th. Stockholders of record on Monday, February 28th will be given a dividend of $...
Is Organon & Co. a good dividend stock?
Organon & Co. pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.13%. The dividend payout ratio of Organon & Co. is...
What guidance has Organon & Co. issued on next quarter's earnings?
Organon & Co. issued an update on its FY 2022 earnings guidance on Thursday, March, 10th. The company provided earnings per share guidance of for t...
What price target have analysts set for OGN?
9 analysts have issued twelve-month price objectives for Organon & Co.'s shares. Their forecasts range from $35.00 to $48.00. On average, they anti...
Who are Organon & Co.'s key executives?
Organon & Co.'s management team includes the following people: Mr. Kevin Ali , CEO & Director (Age 61) Mr. Matthew M. Walsh , Chief Financial O...
Who are some of Organon & Co.'s key competitors?
Some companies that are related to Organon & Co. include Astellas Pharma (ALPMY) , MERCK Kommanditgesellschaft auf Aktien (MKGAF) , Horizon Ther...
Is Organon & Co. a buy right now?
What stocks does MarketBeat like better than Organon & Co.?
8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Organon & Co. stock.#N#View analyst ratings for Organon & Co.
When is Organon & Co.'s next earnings date?
Wall Street analysts have given Organon & Co. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Organon & Co. wasn't one of them.
How were Organon & Co.'s earnings last quarter?
Organon & Co. is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.#N#View our earnings forecast for Organon & Co..
How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?
Organon & Co. (NYSE:OGN) announced its earnings results on Thursday, August, 12th. The company reported $1.72 earnings per share for the quarter, beating analysts' consensus estimates of $1.49 by $0.23.#N#View Organon & Co.'s earnings history.
Is Organon & Co. a good dividend stock?
Organon & Co. declared a quarterly dividend on Thursday, August 12th. Investors of record on Monday, August 23rd will be given a dividend of $0.28 per share on Monday, September 13th. This represents a $1.12 annualized dividend and a yield of 3.15%.
What guidance has Organon & Co. issued on next quarter's earnings?
Organon & Co. pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.15%.#N#View Organon & Co.'s dividend history.
3 Reasons To Buy Organon Stock, Says BofA Analyst
Organon & Co. updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.10 billion-$6.40 billion, compared to the consensus revenue estimate of $6.25 billion.
Organon To Present at Morgan Stanley's 19th Annual Global Healthcare Virtual Conference
Organon & Co (NYSE:OGN), which has recently spun-off from Merck & Co., Inc. (NYSE:MRK), has “inherited a global business across three segments,” namely Women's Health, Legacy and Biosimilars brands, acc...
Organon To Present at Citi's 16th Annual BioPharma Virtual Conference
JERSEY CITY, N.J.-- (BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...
Avestria Ventures Closes Fund I
JERSEY CITY, N.J.-- (BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...
Jeff Auxier Discloses Position in Organon, Curbs Several Top Holdings
SAN FRANCISCO-- (BUSINESS WIRE)-- #femalefounders--Avestria Ventures closes Fund I. The Bay Area-based venture capital firm invests in women's health and female-led life science ventures.
GuruFocus Announces Winner of 2nd-Quarter Warren Buffett Contest
Auxier Asset Management leader Jeff Auxier (Trades, Portfolio) released his second-quarter portfolio last week.
Warren Buffett Sells Biotech Holdings After a Year
GuruFocus is proud to announce that there was one winner of the second-quarter Warren Buffett (Trades, Portfolio) contest: Steak.
What OGN Stock Is Worth
Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its 13F report for the period ending June 30.
Where This Leaves Organon Shareholders
That is probably way too inexpensive for this company. For example, the slide deck indicates that the gross margin will be in the 60% range. Its adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin will be between 36% to 38%. Page 19 of the deck shows that its 2020 adjusted EBITDA was $2.8 billion.
Signals & Forecast
This is too cheap a valuation. For example, Merck trades for about 16 times its trailing-12-month EV/EBITDA. On an adjusted EBITDA basis, it is at about eight times or so. Therefore, even using a 20% discount, Organon stock should be at 6.4 times adjusted EBITDA.
Support, Risk & Stop-loss
There are mixed signals in the stock today. A sell signal was issued from a pivot top point on Thursday, September 02, 2021, and so far it has fallen 0%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD).
Is Organon & Co. stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $30.19 and $28.91. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Organon & Co. finds support just below today's level at $30.19.
What is Organon & Co.'s consensus rating and price target?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Organon & Co. stock to perform well in the short-term.
Do Wall Street analysts like Organon & Co. more than its competitors?
According to the issued ratings of 8 analysts in the last year, the consensus rating for Organon & Co. stock is Buy based on the current 4 hold ratings and 4 buy ratings for OGN. The average twelve-month price target for Organon & Co. is $40.29 with a high price target of $48.00 and a low price target of $35.00.
Do MarketBeat users like Organon & Co. more than its competitors?
Analysts like Organon & Co. stock less than the stock of other Medical companies. The consensus rating score for Organon & Co. is 2.50 while the average consensus rating score for medical companies is 2.72. Learn more#N#on how OGN compares to other companies
Does Organon & Co.'s stock price have much upside?
MarketBeat users like Organon & Co. stock less than the stock of other Medical companies. 53.85% of MarketBeat users gave Organon & Co. an outperform vote while medical companies recieve an average of 67.30% outperform votes by MarketBeat users.
What analysts cover Organon & Co.?
According to analysts, Organon & Co.'s stock has a predicted upside of 20.47% based on their 12-month price targets.
